To the full analysis
Novo Nordisk stock: growth
NOVO-B.CONovo Nordisk reported $45.81B in revenue for fiscal 2025, up 6.4% on the prior year, up 19.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
11.5%
per year from 2006 to 2025, per share 13.7%
Earnings (Annual rate)
15.7%
per year from 2006 to 2025, per share 18%
Free cash flow (Annual rate)
10.4%
per year from 2006 to 2025, per share 12.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 19.5% | 11.1% | 11.5% |
| Revenue per share | 20.7% | 12.7% | 13.7% |
| Earnings | 19.4% | 11.4% | 15.7% |
| Earnings per share | 20.6% | 13.0% | 18.0% |
| Free cash flow | −0.6% | −0.9% | 10.4% |
| Free cash flow per share | 0.4% | 0.5% | 12.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $5.74B | $956.54M | $655.84M |
| 2007 | $6.21B | $1.27B | $1.12B |
| 2008 | $6.77B | $1.43B | $1.61B |
| 2009 | $7.57B | $1.6B | $1.83B |
| 2010 | $9.01B | $2.13B | $2.34B |
| 2011 | $9.83B | $2.53B | $2.67B |
| 2012 | $11.57B | $3.18B | $2.76B |
| 2013 | $12.39B | $3.73B | $3.31B |
| 2014 | $13.16B | $3.93B | $4.06B |
| 2015 | $16B | $5.17B | $4.73B |
| 2016 | $16.57B | $5.62B | $5.94B |
| 2017 | $16.56B | $5.65B | $4.82B |
| 2018 | $16.58B | $5.73B | $4.77B |
| 2019 | $18.09B | $5.77B | $5.27B |
| 2020 | $18.82B | $6.25B | $4.43B |
| 2021 | $20.87B | $7.08B | $7.06B |
| 2022 | $26.23B | $8.23B | $9.51B |
| 2023 | $34.43B | $12.4B | $10.38B |
| 2024 | $43.05B | $14.97B | $10.33B |
| 2025 | $45.81B | $15.18B | $4.3B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2006)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.